Table 1 Comparison of KRAS status (analysis restricted to codon G12D, G12V and G13D) between paired tissue (analysed by standard PCR-based techniques) and plasma samples (analysed by ddPCR).

From: KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

Blood

KRAS WT

KRAS MUT

Total

Tissue

KRAS WT

40 (64.5%)

22 (35.5%)*

62 (63.9%)

KRAS MUT

16 (57.1%)

12 (42.9%)**

28 (28.9%)

KRAS UNK

6 (85.7%)

1 (14.3%)

7 (7.2%)

  Total

62 (63.9%)

35 (36.1%)

97 (100%)

  1. *In 11 cases the absence of tissue KRAS mutation was previously confirmed in both baseline biopsy and resection samples.
  2. **In 3 cases the KRAS mutation which was found in ctDNA involved a different codon compared with the KRAS mutation which was previously detected in the tissue.
  3. Abbreviations: WT: wild-type; MUT: mutant; UNK: unknown.
Back to article page